Skip to content

Study · Non-randomized trial · 2019

4 results

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.

Giorgino F, Shaunik A, Liu M, Saremi A

Diabetes, obesity & metabolism3 Sept 2019Cited by 8 (Europe PMC)

PMID31423722 (opens in a new tab)PMCIDPMC6899526 (opens in a new tab)DOI10.1111/dom.13857 (opens in a new tab)PepBankPUB-31423722
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, the median percentage change in triglycerides at week 30 was a 0.3% increase with iGlarLixi versus a 6.5% increase with insulin glargine (P = 0.035; overall).

    In plain wordsIn patients with diabetes, triglycerides increased less with iGlarLixi than insulin glargine at week 30.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTriglycerides at week 30
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median percentage change in triglycerides
    0.3%
    iGlarLixi, week 30, overall
    Median percentage change in triglycerides
    6.5%
    iGlar, week 30, overall
    P value
    0.035
    between treatments, overall

    Source sentences

    Summary
    At week 30, median percentage change in triglycerides remained nearly unchanged (0.3% increase) with iGlarLixi versus a 6.5% increase with iGlar (P = 0.035; overall);
    2 context sentences
    Summary · context
    This analysis investigated the effect of iGlarLixi [insulin glargine U100 (iGlar) and lixisenatide] versus iGlar on lipid profiles in patients with type 2 diabetes uncontrolled on basal insulin.
    Summary · context
    Data from LixiLan-L were used to estimate changes in fasting lipid levels from baseline to week 30, overall and in patients stratified by achievement of glycaemic targets {2-hour postprandial glucose [≤10, >10 mmoL/L], fasting plasma glucose [≤6.1, >6.1 mmoL/L], HbA1c [≤7, >7% (≤53, >53 mmol/mol)]}.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, total cholesterol showed a trend toward better levels with iGlarLixi versus insulin glargine at week 30.

    In plain wordsIn patients with diabetes, total cholesterol tended toward better levels with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedTotal cholesterol at week 30
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    similarly, trends towards better total and LDL cholesterol levels were observed with iGlarLixi versus iGlar.
    2 context sentences
    Summary · context
    This analysis investigated the effect of iGlarLixi [insulin glargine U100 (iGlar) and lixisenatide] versus iGlar on lipid profiles in patients with type 2 diabetes uncontrolled on basal insulin.
    Summary · context
    Data from LixiLan-L were used to estimate changes in fasting lipid levels from baseline to week 30, overall and in patients stratified by achievement of glycaemic targets {2-hour postprandial glucose [≤10, >10 mmoL/L], fasting plasma glucose [≤6.1, >6.1 mmoL/L], HbA1c [≤7, >7% (≤53, >53 mmol/mol)]}.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with diabetes, LDL cholesterol showed a trend toward better levels with iGlarLixi versus insulin glargine at week 30.

    In plain wordsIn patients with diabetes, LDL cholesterol tended toward better levels with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedLDL cholesterol at week 30
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    similarly, trends towards better total and LDL cholesterol levels were observed with iGlarLixi versus iGlar.
    2 context sentences
    Summary · context
    This analysis investigated the effect of iGlarLixi [insulin glargine U100 (iGlar) and lixisenatide] versus iGlar on lipid profiles in patients with type 2 diabetes uncontrolled on basal insulin.
    Summary · context
    Data from LixiLan-L were used to estimate changes in fasting lipid levels from baseline to week 30, overall and in patients stratified by achievement of glycaemic targets {2-hour postprandial glucose [≤10, >10 mmoL/L], fasting plasma glucose [≤6.1, >6.1 mmoL/L], HbA1c [≤7, >7% (≤53, >53 mmol/mol)]}.
  4. 04HumanObservational studyEfficacy outcome

    In diabetes subgroups achieving glycemic targets, lipid variables except HDL cholesterol improved with iGlarLixi but not insulin glargine.

    In plain wordsIn patients reaching glucose targets, lipid measures except HDL improved with iGlarLixi but not insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedLipid variables in glycemic target subgroups
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In patient subgroups achieving glycaemic targets, all lipid variables except for HDL cholesterol improved with iGlarLixi but not with iGlar.
    2 context sentences
    Summary · context
    This analysis investigated the effect of iGlarLixi [insulin glargine U100 (iGlar) and lixisenatide] versus iGlar on lipid profiles in patients with type 2 diabetes uncontrolled on basal insulin.
    Summary · context
    Data from LixiLan-L were used to estimate changes in fasting lipid levels from baseline to week 30, overall and in patients stratified by achievement of glycaemic targets {2-hour postprandial glucose [≤10, >10 mmoL/L], fasting plasma glucose [≤6.1, >6.1 mmoL/L], HbA1c [≤7, >7% (≤53, >53 mmol/mol)]}.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.